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Abstract
Background: Pulmonary embolism (PE) is a serious complication of acute lympho-
blastic leukemia (ALL). We examined the cumulative incidence and clinical presen-
tation of PE in a well-defined cohort of patients with ALL aged 1-45 years treated 
according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) 
ALL2008 protocol.
Methods: As part of the mandatory toxicity reporting of NOPHO ALL2008, throm-
boembolism including PE was reported consecutively. The cumulative incidence of 
first-time PE was calculated using the Aalen-Johansen estimator during a 2.5-year 
period from ALL diagnosis. We used Fisher’s exact test to examine categorical vari-
ables and Cox logistic regression to estimate hazard ratios (HRs) for PE.
Results: PE was diagnosed in 32 of 1685 patients. The 2.5-year cumulative inci-
dence of first-time PE increased with age: 0.43% (95% CI, 0.18-1.03) in children aged 
1-9 years, 3.28% (95% CI, 1.72-6.22) in children aged 10-17 years, and 7.22% (95% CI, 
4.61-11.21) in adults aged 18-45 years. The majority of PEs, 78% (25/32), occurred 
during asparaginase treatment. HRs adjusted for age and sex were associated with 
male sex (HR, 2.4; 95% CI, 1.0-5.6) and older age (10-17 years: HR 7.5; 95% CI, 2.5-
22.2), 18-45 years: HR, 16.5; 95% CI, 6.1-44.5). In two-thirds of the patients (63%; 
17/27), PE and its treatment had no impact on the administered doses of asparagi-
nase. PE-associated 30-day mortality was 9.4% (95% CI, 1.9-25.0).
Conclusions: Awareness of PE is warranted during ALL treatment. Larger multicenter 
studies are needed to examine predictors of PE in ALL.
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Essentials
• Pulmonary embolism (PE) is a serious complication of acute lymphoblastic leukemia (ALL).
• We observed PE in 32 of 1685 patients aged 1-45 years with ALL.
• Cumulative incidence of PE was 1.9%, and being 7.2% at age 18-45years.
• Mortality of PE was 9.4%, and all fatalities (n = 3) occurred in children.
1  | INTRODUCTION
Current treatment approaches have improved the event-free survival 
rates for children and adults with acute lymphoblastic leukemia (ALL) 
to more than 80% and 74%, respectively.1,2 Treatment of ALL is associ-
ated with toxicity, such as thromboembolism (TE), including pulmonary 
embolism (PE).3-5 TE, and especially PE, is a potentially life-threatening 
event and may impact scheduled treatment for leukemia.6,7 Risk factors 
for PE have not been validated in children, and data in the setting of PE 
in childhood and adulthood ALL are lacking.8 We examined the cumula-
tive incidence and clinical presentation of PE in a well-defined cohort 
of patients with ALL aged 1-45 years treated according to the Nordic 
Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 
protocol. The study is, to our knowledge, the largest observational 
study ever published on PE in children and young adults with ALL.
2  | METHODS AND MATERIALS
We included children and adults with ALL aged 1-45 years treated ac-
cording to the NOPHO ALL2008 protocol.2 The NOPHO ALL2008 
protocol includes Denmark, Estonia, Finland, Iceland, Lithuania, 
Norway, and Sweden. The patients (n = 1812) were diagnosed with 
ALL from July 2008 to February 2016. Patients who developed PE 
during treatment for ALL were identified and compared with patients 
without TE during ALL therapy. The following exclusion criteria were 
used in this study: TE other than PE (n = 122), missing data (n = 4), and 
ALL treatment deviating from the protocol (n = 1). The patients with 
TE, who were excluded from the present study, have been described 
previously.7,9 Eventually, the total study cohort comprised 1685 pa-
tients. The date for the last follow-up was April 1, 2017.
Patient demographics, ALL characteristics, and treatment details 
were retrieved from the NOPHO ALL2008 registry. TE events were reg-
istered at 3-month intervals through mandatory toxicity registration in 
the NOPHO register, with a compliance rate of 98.9%.10 In-depth infor-
mation of the PEs was obtained from the hospitals retrospectively, using 
a standardized data registration form. Cases of symptomatic PE were 
identified through clinical symptoms and confirmed by imaging (com-
puted tomography [CT] or lung scintigraphy). Asymptomatic PE was de-
fined as an incidental finding when imaging was performed due to other 
symptoms without suspicion of PE or as workup due to deep venous 
thrombosis (DVT) elsewhere without associated pulmonary symptoms. 
The date of PE was defined as the date of confirmation of PE by imag-
ing or the death date in cases of PE diagnosed by autopsy. The patients 
included in this study were not screened for PE. Children were defined 
by age below 18 years. Major bleeding was defined by the criteria of the 
ISTH.11 Data on bleeding episodes for each patient were collected the 
following 3 months after the start of anticoagulation.
2.1 | The NOPHO ALL2008 protocol
The NOPHO ALL2008 protocol has been previously described in 
detail elsewhere.2 During the first 21 days of the induction phase, 
patients received dexamethasone or prednisolone. The first intramus-
cular pegylated asparaginase (PegASP) administration (1000 IU/m2) 
was scheduled on day 30. Patients were stratified into a non–high-risk 
(standard or intermediate), or high-risk group. From treatment week 
14, children in the non–high-risk group were randomized to continue 
PegASP every second week (control group) or every sixth week (ex-
perimental group).12 The high-risk group received PegASP at the end of 
each chemotherapy block course (approximately every third to fourth 
week). The NOPHO ALL2008 protocol has no specific recommenda-
tion for thromboprophylaxis, while recommendations for therapeutic 
anticoagulation are available at the NOPHO website.13
2.2 | Statistics
The study population was followed from the diagnosis of ALL until one 
of the following events: the date of the first event (relapse, death, or 
second malignant neoplasm [SMN]); stem cell transplantation in first 
complete remission; lost to follow-up; last follow-up in the NOPHO 
ALL2008 registry; or April 1, 2017. Clinical characteristics were com-
pared between patients with and without PE using Fisher’s exact test. 
The cumulative incidence of first-time PE was calculated using the 
Aalen-Johansen estimator, considering death, relapse, and SMN as 
competing events during a 2.5-year period from ALL diagnosis. We used 
crude and adjusted Cox proportional hazards analysis to estimate the 
hazard ratio (HR) and 95% confidence intervals (CIs) with first-time PE 
as the outcome. The body mass index (BMI) in children was calculated 
using references by Juliusson et al.14
2.3 | Ethics
The NOPHO ALL2008 study was approved by the National 
Medicines Agencies and the relevant national or regional commit-
tees for research ethics in each participating country (Clinical Trial 
Registration: EudraCT 2008-003235-20 and 2011-000908-18).
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3  | RESULTS
In total, 32 of 1685 patients developed PE. In 63% (n = 20) concomi-
tant DVT was not observed. One patient had a cerebral sinovenous 
thrombosis, DVT, and PE at the same time. The diagnosis of PE was 
confirmed by CT (n = 29), lung scintigraphy (n = 1), and autopsy 
(n = 2). All DVTs were confirmed by ultrasonography. In 3 patients, 
diagnosis of PE was incidental.
The 2.5-year cumulative incidence of first-time PE during ther-
apy was 1.91% (95% CI, 1.35-2.69). Increasing age was associated 
with a higher risk of PE (Figure 1). Children aged 1-9 years and 
10-17 years experienced PE corresponding to a 2.5-year cumulative 
incidence of 0.43% (95% CI, 0.18-1.03) and 3.28% (95% CI, 1.72-
6.22), respectively. PE occurred with the highest incidence of 7.22% 
(95% CI, 4.61-11.21) among adults (18-45 years).
Eighteen patients (56%; 18/32) had infection at the diagno-
sis of PE. Of those, 8 patients (44%; 8/18) had positive blood cul-
tures. Immobilization ≥3 days was reported in 5 cases at time of PE. 
Smoking (n = 2) and oral contraceptive use (n = 2) were additional 
risk factors in adults (n = 18). D-dimer at the time of PE diagnosis 
was elevated (cutoff >0.5 mg/L) in all but 1 of 23 cases with available 
D-dimer analyses.
The majority of PE cases in the non–high-risk ALL treatment group 
occurred during consolidation I (protocol weeks 5-13) and during 
maintenance I (protocol weeks 20-57) (Figure 2). In these phases of 
treatment, patients were under concomitant PegASP and steroid 
treatment. Five of 6 patients who received high-risk chemotherapy 
developed their PE after the first chemotherapy block A. (Figure 2). 
In 78% (25/32) of PE cases, PE occurred within 4 weeks from the last 
PegASP administration. Two thirds of the patients with available data 
F I G U R E  1   2.5-year cumulative incidence of PE is 0.43% (95% 
CI, 0.18-1.03), 3.28% (95% CI, 1.72-6.22), and 7.22% (95% CI, 4.61-
11.21) in patients aged 1-9 y, 10-17 y, and 18-45 y, respectively. 
ALL, acute lymphoblastic leukemia; CI, confidence interval; PE, 
pulmonary embolism
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F I G U R E  2   Time point for diagnosis of pulmonary embolism (n = 32) in relationship with an overview of the treatment phases of the 
NOPHO ALL2008 protocol. Treatment weeks at the bottom of the figure apply to non–high-risk treatment. *The treatment with PegASP 
in the non–high-risk group started postinduction on day 30 and continued until treatment week 33 (as shown at the bottom of the figure 
with the horizontal line). The patients in the high-risk group received PegASP at the end of each high-risk block. Treatment phases with 
steroids are indicated in gray. The triangles and the dots are explained at the bottom of the figure. Children are defined as 1-17 y old; 
adults 18-45 y old. DI-I, first delayed intensification; DI-II, second delayed intensification; I-D, induction therapy with dexamethasone; I-P, 
induction therapy with prednisolone; IR, intermediate risk protocol; Maint-I, first maintenance; Maint-II, second maintenance; PE, pulmonary 
embolism; PegASP, pegylated asparaginase; SCT, stem cell transplantation
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TA B L E  1   Clinical characteristics, univariate Cox regression, and Cox regression adjusted for age and sex in ALL patients (1-45 y) with PE 
(n = 32) and without PE (n = 1653)
Factor PE n = 32 (%) No PE n = 1653 (%) P value
HR (95% CI)
Univariate Cox 
regression
 Cox regression adjusted 
for age and sex
Age, ya 
1-9 5 (15.6) 1155 (69.9) <.001 Ref. Ref.
10-17 9 (28.1) 265 (16.0) 7.8 (2.6-23.3) 7.5 (2.5-22.2)
18-45 18 (56.3) 233 (14.1) 17.7 (6.6-47.6) 16.5 (6.1-44.5)
Sex
Female 7 (21.9) 747 (45.2) .01 Ref. Ref.
Male 25 (78.1) 906 (54.8) 2.9 (1.2-6.7) 2.4 (1.0-5.6)
ALL phenotype
B-precursor 20 (62.5) 1393 (84.3) .003 Ref. Ref.
T-cell/bilineage 12 (37.5) 260 (15.7) 3.2 (1.6-6.6) 1.6 (0.8-3.3)
Inductionb 
Prednisolone 19 (59.4) 1285 (78.5) .05 Ref. Ref.
Dexamethasone 13 (40.6) 352 (21.5) 2.5 (1.3-5.1) 1.3 (0.6-2.7)
WBC at ALL diagnosis‡ 
<100 × 109/L 26 (81.3) 1429 (86.5) .43 Ref. Ref.
≥100 × 109/L 6 (18.8) 223 (13.5) 1.5 (0.6-3.7) 1.2 (0.5-2.8)
ALL therapy after day 29§ 
Non–high-risk 26 (81.3) 1343 (82.3) .82 Ref. Ref.
High-risk 6 (18.8) 288 (17.7) 1.1 (0.5-2.7) 0.5 (0.2-1.3)
Residual disease after day 29 ¶ 
<5% 30 (93.8) 1503 (92.7) 1.0 Ref. Ref.
≥5% 2 (6.3) 118 (7.3) 0.9 (0.2-3.7) 0.4 (0.1-1.6)
Mediastinal masses**
No 25 (78.1) 1516 (92.9) .007 Ref. Ref.
Yes 7 (21.9) 116 (7.1) 3.6 (1.6-8.4) 1.9 (0.8-4.5)
Enlarged lymph nodes ≥ 3cm†† 
No 26 (86.7) 1510 (93.0) .16 Ref. Ref.
Yes 4 (13.3) 114 (7.0) 2.1 (0.7-6.0) 1.4 (0.5-4.0)
BMI†† 
Normal weight 20 (62.5) 1400 (85.4) <.001 Ref. Ref.
Underweight (<−2SD) 0 (0) 110 (6.7) 0 0
Overweight (> +2SD) 12 (37.5) 129 (7.9) 6.4 (3.1-13.1) 2.2 (0.9-4.9)
Abbreviations: ALL, acute lymphoblastic leukemia; BMI, body mass index; CI, confidence interval; HR, hazard ratio; PE, pulmonary embolism; Ref., 
reference; SD, standard deviation; WBC, white blood cell count.
aAge at ALL diagnosis. 
bTwo patients without PE are not included—1 patient received no steroid treatment in induction due to viral infection, and another patient had 
modified induction. Data are not available in an additional 14 patients without PE.Data not available in following number of patients without PE: 
‡n = 1, 
§n = 22, 
¶n = 32, 
**n = 21, 
††n = 29, 
§§n = 14. 
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(63%; 15/24) received steroids at the time or within 14 days before PE 
diagnosis. Demographic characteristics of patients with and without 
PE are shown in Table 1. Patients with PE were older with a higher 
proportion of male sex, had a higher BMI, a higher proportion of T-cell 
ALL and mediastinal mass compared with patients without PE.
In univariate regression analyses, increasing age, male sex, over-
weight, T-cell ALL, induction with dexamethasone, and the presence 
of lymphadenopathy and mediastinal mass were associated with PE 
development (Table 1). No other predictors to PE than male sex (HR, 
2.4; 95% CI, 1.0-5.6) and older age (10-17 years: HR, 7.5; 95% CI, 
2.5-22.2), 18-45 years: HR, 16.5; 95% CI 6.1-44.5) were identified in 
analyses adjusted for sex and age (Table 1).
Three children with PE died (n = 3/32) corresponding to PE-
associated 30-day mortality of 9.4% (95% CI, 1.9-25.0). PE directly 
caused the death of a 1-year-old boy with respiratory compromise 
and cardiac arrest. PE was a contributing factor to death caused by 
septicemia in 2 children: a 4-year-old boy was diagnosed with PE by 
autopsy, and a 5-year-old girl had PE confirmed by CT while on ex-
tracorporeal membrane oxygenation support. In our study, patients 
with PE (n = 29) were treated with low-molecular-weight heparin 
(LMWH) (n = 27) or unfractionated heparin (n = 2). Non–K-vitamin 
antagonists after initial LMWH treatment were administered in 2 
adults and in one 17-year-old patient.
Two minor bleedings (epistaxis) and a major bleeding were reg-
istered during the therapeutic anticoagulation period. A 13-year-old 
boy experienced hemothorax during catheter-directed thromboly-
sis. This child fully recovered. No fatal bleedings occurred. None of 
the patients diagnosed with PE at the pediatric departments had re-
ceived primary antithrombotic prophylaxis, while 4 patients treated 
at the adult clinics were on LMWH prophylaxis before the diagnosis 
of PE. In two thirds of our patients (63%; 17/27), PE and/or its treat-
ment had no impact on the administered total dose of PegASP.
4  | DISCUSSION
Our study is the first we are aware of to report the cumulative inci-
dence of PE in ALL patients treated according to a uniform protocol. 
In pediatric populations, the incidence of PE peaks in infancy (age 
<1 year) and adolescence.15 In our cohort, which does not include 
infants <1 year of age, the highest 2.5-year cumulative incidence was 
not in children but in adults aged 18-45 years, which is not a surprise 
since PE is more common in adults.16
In this study, most PEs occurred during concomitant treatment 
with asparaginase and steroids. Asparaginase decreases anticoagu-
lant, procoagulant, and fibrinolytic protein levels, especially reduc-
tion in antithrombin results in hypercoagulability and increased risk 
of thrombosis.17 Exposure to asparaginase, increasing age, T-cell 
leukemia, mediastinal mass, obesity, and use of dexamethasone in 
induction have previously been pointed out as possible factors for 
increased risk of TE in ALL.18-22 In our study, older age was associ-
ated with a higher risk of PE. We also observed a greater proportion 
of male sex in patients with PE. Male predominance in PE has not 
been previously reported in children or young adults without malig-
nancies.16,23 To date, no other studies have focused on PE in pedi-
atric and young adult ALL; thus, our finding needs to be confirmed 
and should be interpreted with caution due to few observations and 
limited statistical power in our study. In a study by Prasca et al,22 
obesity was a significant risk factor to DVT in children with ALL. A 
tendency toward an association between increased BMI and PE was 
observed, although not statistically significant. However, overweight 
can be an amenable factor, and therefore this observation should be 
investigated in larger studies, too. In our cohort, PEs occurred after 
induction and continued during the first 6 months of ALL treatment, 
which coincides with PegASP treatment. Reexposure to aspara-
ginase with LMWH cover has previously been reported to be safe 
once symptoms of TE have resolved.24 In our patients, treatment 
with LMWH was without major complications, and in most cases, 
asparaginase was not truncated.
In conclusion, PE is a potentially fatal complication during the 
treatment of ALL. Our population-based study emphasizes the need 
for awareness of PE during the exposure of asparaginase and steroids.
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